257 related articles for article (PubMed ID: 23672493)
1. Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells.
Tanaka M; Kataoka H; Yano S; Ohi H; Kawamoto K; Shibahara T; Mizoshita T; Mori Y; Tanida S; Kamiya T; Joh T
BMC Cancer; 2013 May; 13():237. PubMed ID: 23672493
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
[TBL] [Abstract][Full Text] [Related]
4. PEA‑15 contributes to the clinicopathology and AKT‑regulated cisplatin resistance in gastric cancer.
Jiang X; Zhang C; Li W; Jiang D; Wei Z; Lv M; Xie X; Sun X
Oncol Rep; 2019 Mar; 41(3):1949-1959. PubMed ID: 30569123
[TBL] [Abstract][Full Text] [Related]
5. Anticancer Effects of a New Aminosugar-conjugated Platinum Complex Agent Against Cisplatin-resistant Gastric Cancer.
Hayashi N; Kataoka H; Yano S; Kikuchi JI; Tanaka M; Nishie H; Kinoshita Y; Hatano M; Nomoto A; Ogawa A; Inoue M; Mizoshita T; Shimura T; Mori Y; Kubota E; Tanida S; Joh T
Anticancer Res; 2016 Nov; 36(11):6005-6009. PubMed ID: 27793927
[TBL] [Abstract][Full Text] [Related]
6. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line.
Wen J; Zheng B; Hu Y; Zhang X; Yang H; Luo KJ; Zhang X; Li YF; Fu JH
Oncol Rep; 2009 Jul; 22(1):65-71. PubMed ID: 19513506
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism.
Maeda S; Sugiura T; Saikawa Y; Kubota T; Otani Y; Kumai K; Kitajima M
Cancer Sci; 2004 Aug; 95(8):679-84. PubMed ID: 15298732
[TBL] [Abstract][Full Text] [Related]
8. The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer.
Geng M; Wang L; Chen X; Cao R; Li P
Diagn Pathol; 2013 Dec; 8():198. PubMed ID: 24326092
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic basis for overcoming platinum resistance using copper chelating agents.
Liang ZD; Long Y; Tsai WB; Fu S; Kurzrock R; Gagea-Iurascu M; Zhang F; Chen HH; Hennessy BT; Mills GB; Savaraj N; Kuo MT
Mol Cancer Ther; 2012 Nov; 11(11):2483-94. PubMed ID: 22914438
[TBL] [Abstract][Full Text] [Related]
10. LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression.
Wang X; Li H; Shi J
Biomed Res Int; 2019; 2019():8645153. PubMed ID: 31275988
[TBL] [Abstract][Full Text] [Related]
11. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
12. The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway.
Park J; Ko YS; Yoon J; Kim MA; Park JW; Kim WH; Choi Y; Kim JH; Cheon Y; Lee BL
Gastric Cancer; 2014; 17(3):423-30. PubMed ID: 24202965
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of c-Jun protein plays an instrumental role in chemoresistance of cancer cells.
Xia Y; Yang W; Bu W; Ji H; Zhao X; Zheng Y; Lin X; Li Y; Lu Z
J Biol Chem; 2013 Jul; 288(27):19321-9. PubMed ID: 23678002
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
[TBL] [Abstract][Full Text] [Related]
15. Novel Pt(IV) complexes to overcome multidrug resistance in gastric cancer by targeting P-glycoprotein.
Cao X; Li R; Xiong H; Su J; Guo C; An T; Zong H; Zhao R
Eur J Med Chem; 2021 Oct; 221():113520. PubMed ID: 34029775
[TBL] [Abstract][Full Text] [Related]
16. Suppression of fumarate hydratase activity increases the efficacy of cisplatin-mediated chemotherapy in gastric cancer.
Yu HE; Wang F; Yu F; Zeng ZL; Wang Y; Lu YX; Jin Y; Wang DS; Qiu MZ; Pu HY; Kang TB; Xie D; Ju HQ; Xu RH; Luo HY
Cell Death Dis; 2019 May; 10(6):413. PubMed ID: 31138787
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of FAM3B Promotes Cisplatin Resistance in Gastric Cancer by Inducing Epithelial-Mesenchymal Transition.
Song C; Duan C
Med Sci Monit; 2020 May; 26():e921002. PubMed ID: 32442162
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro.
Zhao Q; Zhang H; Li Y; Liu J; Hu X; Fan L
J Exp Clin Cancer Res; 2010 Aug; 29(1):118. PubMed ID: 20799994
[TBL] [Abstract][Full Text] [Related]
19. Dual-target platinum(IV) complexes reverse cisplatin resistance in triple negative breast via inhibiting poly(ADP-ribose) polymerase (PARP-1) and enhancing DNA damage.
Li R; Zhao W; Jin C; Xiong H
Bioorg Chem; 2023 Apr; 133():106354. PubMed ID: 36720184
[TBL] [Abstract][Full Text] [Related]
20. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
